West Pharmaceutical Services (FRA:WPS) Long-Term Capital Lease Obligation : €76 Mil (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is West Pharmaceutical Services Long-Term Capital Lease Obligation?

West Pharmaceutical Services's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €76 Mil.

West Pharmaceutical Services's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (€78 Mil) to Dec. 2023 (€77 Mil) and declined from Dec. 2023 (€77 Mil) to Mar. 2024 (€76 Mil).

West Pharmaceutical Services's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (€56 Mil) to Dec. 2022 (€88 Mil) but then declined from Dec. 2022 (€88 Mil) to Dec. 2023 (€77 Mil).

West Pharmaceutical Services Long-Term Capital Lease Obligation Historical Data

The historical data trend for West Pharmaceutical Services's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

West Pharmaceutical Services Long-Term Capital Lease Obligation Chart

West Pharmaceutical Services Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

56.16

49.65

55.76

87.79

77.49

West Pharmaceutical Services Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															83.97	80.58	77.77	77.49	75.81

West Pharmaceutical Services (FRA:WPS) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

West Pharmaceutical Services Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of West Pharmaceutical Services's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

West Pharmaceutical Services (FRA:WPS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » West Pharmaceutical Services Inc (FRA:WPS) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

WST:USA WPS:Germany

Address

530 Herman O. West Drive, Exton, PA, USA, 19341-0645

Website

https://www.westpharma.com

West Pharmaceutical Services is a Pennsylvania-based medical supplies company that operates as a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West develops, manufactures, and distributes elastomer-based supplies for the containment and administration of injectable drugs, including basic equipment such as syringes, stoppers, and plungers, along with somewhat more complicated devices including auto-injectors and other self-injection platforms. The company reports in two segments: proprietary products (82% of 2021 sales) and contract-manufactured products (18%). It generates 55% of its revenue from international markets and 45% from the United States.